{
    "clinical_study": {
        "@rank": "30252", 
        "arm_group": [
            {
                "arm_group_label": "DMB-3111", 
                "arm_group_type": "Experimental", 
                "description": "6 mg/kg is once given in intravenous drip infusion taking 90 min"
            }, 
            {
                "arm_group_label": "trastuzumab", 
                "arm_group_type": "Active Comparator", 
                "description": "6 mg/kg is once given in intravenous drip infusion taking 90 min"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is a randomized Trastuzumab-controlled double-blind parallel-group study."
        }, 
        "brief_title": "Bioequivalence Study Evaluating the Pharmacokinetics of DMB-3111 and Trastuzumab in Healthy Japanese Male Adults", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy Volunteer", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Healthy Japanese male adults\n\n          2. Body Mass Index (BMI) between 17.6 and 26.4 kg/m\u00b2 at the time of screening BMI = Body\n             Weight (kg)/[Height (m)]\u00b2\n\n          3. The individual who freely consents to participate after receiving a detailed\n             explanation of the clinical study and completely understanding thereof, and who has\n             capacity to follow precautions and provide written consent.\n\n        Exclusion Criteria:\n\n          1. History of hypersensitivity to components of Trastuzumab or diphenhydramine or any\n             other drug\n\n          2. Use of any ethical drug within 2 weeks before investigational product administration\n             or any over-the-counter drug within 1 week before investigational product\n             administration that would affect study participation in the opinion of the\n             investigator or subinvestigators (except for diphenhydramine, which will be used\n             concomitantly in the present clinical trial and any drug applied locally and having\n             no systemic actions)\n\n          3. History of allergic symptoms such as bronchial asthma and urticaria that would affect\n             study participation in the opinion of the investigator or subinvestigators\n\n          4. History of cardiac disorders, hypertension, coronary artery disease (e.g., myocardial\n             infarction, angina), and/or vascular disorder; ongoing palpitations, shortness of\n             breath, and/or tachycardia"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "39 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "70", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 27, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02100917", 
            "org_study_id": "DMB-3111-2", 
            "secondary_id": "JapicCTI-142486"
        }, 
        "intervention": [
            {
                "arm_group_label": "DMB-3111", 
                "intervention_name": "DMB-3111", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "trastuzumab", 
                "intervention_name": "trastuzumab", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Trastuzumab"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Bioequivalence", 
            "Biosimilarity", 
            "Similarity", 
            "Pharmacokinetics", 
            "Phase I", 
            "Trastuzumab", 
            "Healthy Male Volunteers", 
            "Single-dose", 
            "HER-2", 
            "Oncology"
        ], 
        "lastchanged_date": "April 3, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Fukuoka", 
                    "country": "Japan"
                }
            }
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "2", 
        "other_outcome": {
            "measure": "Incidence of anti-trastuzumab antibodies (ADAs)", 
            "safety_issue": "Yes", 
            "time_frame": "Day1-71"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Area Under the Concentration-Time (AUC)", 
                "safety_issue": "No", 
                "time_frame": "Day1-71"
            }, 
            {
                "measure": "Maximum observed serum concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "Day1-71"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02100917"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Area under the concentration-time curve (AUC) from 0 to time of the last measurable concentration", 
                "safety_issue": "No", 
                "time_frame": "Day1-71"
            }, 
            {
                "measure": "Area under the concentration-time curve (AUC) from 0 to infinity", 
                "safety_issue": "No", 
                "time_frame": "Day1-71"
            }, 
            {
                "measure": "Time to reach the peak concentration (tmax)", 
                "safety_issue": "No", 
                "time_frame": "Day1-71"
            }, 
            {
                "measure": "Mean residence time (MRT) from 0 to final sampling time point", 
                "safety_issue": "No", 
                "time_frame": "Day1-71"
            }, 
            {
                "measure": "Mean residence time (MRT) from 0 to infinity", 
                "safety_issue": "No", 
                "time_frame": "Day1-71"
            }, 
            {
                "measure": "elimination rate constant (kel)", 
                "safety_issue": "No", 
                "time_frame": "Day1-71"
            }, 
            {
                "measure": "Elimination half life (t1/2)", 
                "safety_issue": "No", 
                "time_frame": "Day1-71"
            }, 
            {
                "measure": "Clearance (CL)", 
                "safety_issue": "No", 
                "time_frame": "Day1-71"
            }, 
            {
                "measure": "Incidence of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Day1-71"
            }
        ], 
        "source": "Meiji Seika Pharma Co., Ltd.", 
        "sponsors": {
            "collaborator": {
                "agency": "Dong-A", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Meiji Seika Pharma Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}